David Filmore


20 Years of Experience

About

@MedtechDavid, Executive Editor of MedTech Strategist Market Pathways has been covering the medical technology sector as a writer and editor for about 20 years. David specializes in the regulatory and reimbursement dynamics that impact device and diagnostics companies' ability to succeed in the marketplace. He joined MedTech Strategist in 2019 to launch Market Pathways as the premier publication covering policy and market access issues in medtech.

David previously served as the executive editor/editor-in-chief of The Gray Sheet and Medtech Insight, and he spent years as a writer for The Gray Sheet, reporting on policies impacting the device industry from FDA, CMS, OIG, Europe, and elsewhere around the world. He frequently talks to leaders in government and industry and enjoys digging into the details of developing healthcare policies to understand how they will play out in the market. Earlier in his career, David was an editor with the American Chemical Society, where he analyzed issues for professionals in the pharmaceutical industry and analytical instrumentation space. He has also worked in the drug industry and has a degree in chemistry.

Articles from David Filmore:

Regulatory & Reimbursement

Pathways’ Picks October 21: NCD Pipeline, FDA Slowdown, EUDAMED Watch

CMS posted its first “NCD Wait List” of pending Medicare coverage determinations, and two proposed coverage decisions all in the same day. Meanwhile, pandemic burdens are starting to show up in FDA’s broader device review performance, and European policymakers took another baby step toward the much anticipated EU-wide device database. That and more in this week’s Pathways’ Picks.

Read Article